Get the Stockscreener App
13.08
0.62%
0.08
After Hours:
13.02
-0.06
-0.46%
Syndax Pharmaceuticals Inc stock is traded at $13.08, with a volume of 1.10M.
It is up +0.62% in the last 24 hours and down -4.04% over the past month.
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. The company's product candidates are entinostat which has direct effects on both cancer cells and immune regulatory cells, SNDX-6352 and SNDX-6352, an anti-CSF-1R monoclonal antibody, to enhance the body's immune response on tumors that have shown sensitivity to immunotherapy. Business activity of the group is primarily functioned through the region of United States.
See More
Previous Close:
$13.00
Open:
$13.14
24h Volume:
1.10M
Relative Volume:
0.57
Market Cap:
$1.12B
Revenue:
$139.71M
Net Income/Loss:
$-209.36M
P/E Ratio:
-4.4189
EPS:
-2.96
Net Cash Flow:
$-160.60M
1W Performance:
-0.23%
1M Performance:
-4.04%
6M Performance:
-44.79%
1Y Performance:
-39.58%
1-Day Range:
$12.92
$13.21
1-Week Range:
$12.06
$13.24
52-Week Range:
$12.06
$25.34
Syndax Pharmaceuticals Inc Stock (SNDX) Company Profile
Name
Syndax Pharmaceuticals Inc
Sector
Industry
Phone
781-419-1400
Address
35 GATEHOUSE DRIVE, WALTHAM, MA
Compare SNDX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SNDX
Syndax Pharmaceuticals Inc
|
13.08 | 1.12B | 139.71M | -209.36M | -160.60M | -2.96 |
|
VRTX
Vertex Pharmaceuticals Inc
|
422.00 | 108.68B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
681.58 | 74.90B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
640.52 | 38.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
246.27 | 31.76B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
111.93 | 26.83B | 3.30B | -501.07M | 1.03B | -2.1146 |
Syndax Pharmaceuticals Inc Stock (SNDX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-24-24 | Initiated | UBS | Buy |
| Jun-28-24 | Initiated | Jefferies | Buy |
| Jan-31-24 | Downgrade | Scotiabank | Sector Outperform → Sector Perform |
| Dec-22-23 | Initiated | Mizuho | Buy |
| Oct-25-23 | Initiated | BofA Securities | Buy |
| Oct-11-23 | Initiated | Goldman | Buy |
| Jul-27-23 | Initiated | Scotiabank | Sector Outperform |
| Jul-11-23 | Initiated | Guggenheim | Buy |
| Apr-17-23 | Resumed | BTIG Research | Buy |
| Jan-31-23 | Initiated | Stifel | Buy |
| Jan-03-23 | Initiated | JP Morgan | Overweight |
| Jul-28-22 | Resumed | B. Riley Securities | Buy |
| Apr-11-22 | Initiated | H.C. Wainwright | Buy |
| Feb-15-22 | Initiated | Goldman | Buy |
| Jun-04-21 | Resumed | Robert W. Baird | Outperform |
| May-25-21 | Initiated | Citigroup | Buy |
| Feb-18-21 | Initiated | B. Riley Securities | Buy |
| Dec-03-20 | Initiated | Stifel | Buy |
| May-22-20 | Upgrade | Citigroup | Neutral → Buy |
| May-22-20 | Downgrade | H.C. Wainwright | Buy → Neutral |
| May-18-20 | Downgrade | Citigroup | Buy → Neutral |
| May-11-20 | Reiterated | H.C. Wainwright | Buy |
| Mar-04-20 | Initiated | Barclays | Overweight |
| Jan-13-20 | Reiterated | H.C. Wainwright | Buy |
| Mar-08-19 | Reiterated | H.C. Wainwright | Buy |
| Jan-04-19 | Initiated | Robert W. Baird | Outperform |
| Jan-05-18 | Initiated | B. Riley FBR, Inc. | Buy |
| Mar-16-17 | Initiated | FBR & Co. | Outperform |
| Mar-02-17 | Initiated | Instinet | Buy |
| Oct-07-16 | Initiated | Guggenheim | Buy |
| Mar-28-16 | Initiated | Citigroup | Buy |
| Mar-28-16 | Initiated | JMP Securities | Mkt Outperform |
| Mar-28-16 | Initiated | Morgan Stanley | Overweight |
View All
Syndax Pharmaceuticals Inc Stock (SNDX) Latest News
Syndax Pharmaceuticals (FRA:1T3) Net-Net Working Capital : €3.67 (As of Sep. 2024) - GuruFocus.com
How the (SNDX) price action is used to our Advantage - Stock Traders Daily
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Short Interest Update - MarketBeat
Syndax Pharmaceuticals (FRA:1T3) Price-to-Operating-Cash-Fl - GuruFocus.com
Syndax Pharmaceuticals (FRA:1T3) ROE % Adjusted to Book Val - GuruFocus.com
Assenagon Asset Management S.A. Has $27.29 Million Stock Position in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) - MarketBeat
Incyte, Syndax get FDA okay for 9 mg, 22 mg Niktimvo vials - MSN
Incyte's and Syndax's Graft Disease Treatment Niktimvo Gets FDA Approval for Vial Sizes - Marketscreener.com
Incyte and Syndax Announce U.S. Food and Drug Administration (FDA) Approval of Niktimvotm (axatilimab-csfr) 9 mg and 22 mg Vial Sizes - Lelezard
FDA Approves Niktimvo: Breakthrough Treatment for Chronic GVHD Shows 75% Response Rate - StockTitan
Syndax Pharmaceuticals' SWOT analysis: stock poised for growth amid AML breakthroughs - Investing.com Nigeria
Syndax Pharmaceuticals (FRA:1T3) Cash From Discontinued Inv - GuruFocus.com
Syndax Pharmaceuticals' SWOT analysis: stock poised for growth amid AML breakthroughs By Investing.com - Investing.com South Africa
SNDX stock touches 52-week low at $12.38 amid market challenges - Investing.com Nigeria
Syndax Pharmaceuticals (NASDAQ:SNDX) Reaches New 1-Year LowHere's Why - MarketBeat
Syndax Achieves Dual FDA Approvals for Breakthrough Cancer & GVHD Treatments in Major Growth Milestone - StockTitan
Syndax Pharmaceuticals (FRA:1T3) Other Current Receivables : €4.23 Mil (As of Sep. 2024) - GuruFocus.com
Investing in Syndax Pharmaceuticals (NASDAQ:SNDX) five years ago would have delivered you a 53% gain - Yahoo Finance
Syndax Pharmaceuticals' SWOT analysis: stock poised for growth amid challenges - Investing.com India
Syndax Pharmaceuticals (NASDAQ:SNDX) Given New $16.00 Price Target at Scotiabank - MarketBeat
Kuehn Law Encourages Investors of Syndax Pharmaceuticals, Inc. to Contact Law Firm - The Eastern Progress Online
Where are the Opportunities in (SNDX) - Stock Traders Daily
Syndax Pharmaceuticals CEO to Present at J.P. Morgan Healthcare Conference 2025 - StockTitan
Jefferies maintains Buy rating on Syndax stock with $43 target By Investing.com - Investing.com Nigeria
Syndax Pharmaceuticals Awards 123,100 Stock Options to New Hires in Growth Initiative - StockTitan
Syndax Pharmaceuticals (NASDAQ:SNDX) Shares Up 4.1%What's Next? - MarketBeat
Stifel Financial Corp Purchases Shares of 16,976 Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) - Defense World
Analysts Set Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Price Target at $36.90 - MarketBeat
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Receives Consensus Rating of “Moderate Buy” from Analysts - Defense World
SNDX stock touches 52-week low at $12.75 amid market challenges - Investing.com Canada
Syndax Pharmaceuticals (NASDAQ:SNDX) Sets New 1-Year LowWhat's Next? - MarketBeat
Syndax Pharmaceuticals, Inc. Announces Cessation of Catherine Madigan as Chief Medical Officer - Marketscreener.com
Geode Capital Management LLC Boosts Holdings in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) - Defense World
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Shares Bought by Geode Capital Management LLC - MarketBeat
Syndax Pharmaceuticals (NASDAQ:SNDX) Shares Down 2.6%Should You Sell? - MarketBeat
Barclays PLC Purchases 110,535 Shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) - MarketBeat
Syndax Pharmaceuticals CMO position eliminated By Investing.com - Investing.com Canada
Syndax Pharmaceuticals CMO position eliminated - Investing.com
Syndax Pharmaceuticals' SWOT analysis: stock poised for growth amid FDA approvals - Investing.com
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Is Investigating Syndax Pharmaceuticals, Inc. (NASDAQ: SNDX) for Potential Breaches of Fiduciary Duty By Its Board of Directors - cnhinews.com
Franklin Resources Inc. Has $34.95 Million Stock Position in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) - MarketBeat
SNDX stock touches 52-week low at $13.26 amid market challenges - Investing.com Canada
State Street Corp Increases Stock Position in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) - MarketBeat
Fmr LLC Has $948,000 Holdings in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) - Defense World
Syndax Pharmaceuticals' SWOT analysis: biotech stock poised for growth amid challenges - Investing.com India
(SNDX) Technical Pivots with Risk Controls - Stock Traders Daily
Syndax Pharmaceuticals Inc Stock (SNDX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.65%
4.62%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):